S-1: SRx Health Faces Going Concern Amidst Deep Losses

SRx Health Solutions, Inc. reports substantial doubt about its ability to continue as a going concern, driven by significant net losses, negative operating cash flows, and Canadian subsidiary CCAA proceedings.

Summary

• SRx Health Solutions, Inc. (formerly Better Choice Company Inc.) operates a specialty pharmacy business (SRx Canada) and a pet health and wellness business (Halo).
• The company reported a net loss of $29.7 million for the nine months ended June 30, 2025, a 169% increase from $11.1 million in the prior year.
• Net sales decreased by $76.0 million, or 65%, to $41.1 million for the nine months ended June 30, 2025, primarily due to liquidity constraints limiting high-cost specialty medication purchases and dispensing.
• SRx Canada, the Canadian healthcare services provider, initiated proceedings under the Companies Creditors Arrangement Act (CCAA) on August 12, 2025, due to liquidity constraints and inability to refinance maturing obligations.
• The CCAA proceedings include a stay of proceedings, appointment of a monitor, debtor-in-possession (DIP) financing of up to $1.75 million, and a sale process for SRx Canada's business or assets.
• Halo, the U.S. pet health and wellness subsidiary, continues to experience significant liquidity constraints and operating losses, remaining reliant on external financing.
• The company completed a reverse merger with Better Choice Company Inc. on April 24, 2025, with SRx Canada identified as the accounting acquirer.
• A preliminary bargain purchase gain of $1.69 million was recognized from the reverse merger, as the fair value of net assets acquired exceeded consideration transferred.
• The company sold substantially all assets of its Asia pet food business for $8.1 million, including $6.5 million cash and a 5-year royalty agreement, on April 16, 2025.
• Significant goodwill impairment of $19.7 million was recognized for the Pharmacy and Prescription Drug Sales reporting unit for the year ended September 30, 2024, due to loss of a key contract and challenging industry dynamics.
• The company is offering up to 101,865,909 shares of common stock for resale by selling stockholders, representing approximately 51% of total fully diluted outstanding common stock.
• Outstanding common stock as of November 5, 2025, was 24,992,539 shares, with a fully diluted count of 199,846,505 shares assuming exercise/conversion of all dilutive securities.
• The company received a notice from NYSE American on October 14, 2025, regarding non-compliance with continued listing standards (stockholders' equity below $4 million).
• The company has until November 13, 2025, to submit a plan to regain NYSE American compliance by July 14, 2026.
• Cash and cash equivalents were $0.9 million as of June 30, 2025, up from $0.1 million at June 30, 2024.
• Cash used in operating activities was $15.7 million for the nine months ended June 30, 2025, compared to cash provided of $0.6 million in the prior year period.
• The company was not in compliance with CWB loan covenants as of June 30, 2025, and September 30, 2024, leading to the classification of $23.1 million in CWB loans as current liabilities.
• The company issued $7.65 million in senior secured convertible notes (July PIPE Financing) and warrants for 21,338,062 shares on July 7, 2025.
• On October 27, 2025, the company entered into the October PIPE Financing, issuing 19,035 shares of Series A Convertible Preferred Stock and warrants for 54,527,811 shares for $15.23 million.
• An Equity Line of Credit (ELOC) agreement with Keystone Capital Partners, LLC was amended on October 28, 2025, increasing the total commitment from $50 million to $1.0 billion, with a $20.0 million convertible promissory note issued as consideration.

Sentiment

Score: 2

Explanation: The company is in severe financial distress, evidenced by substantial net losses, negative operating cash flow, a 'going concern' warning, and its primary Canadian subsidiary entering creditor protection (CCAA). While there are ongoing capital raising efforts and asset sales, these are reactive measures to a critical liquidity crisis and covenant breaches. The significant dilution from new share issuances and the risk of NYSE delisting further compound the negative outlook.

Positives

• The company recognized a preliminary bargain purchase gain of $1.69 million from the reverse merger, indicating assets acquired were valued higher than the consideration paid.
• Proceeds from the sale of Halo's Asia business assets totaled $8.1 million, including $6.5 million cash and a 5-year royalty agreement, improving liquidity.
• Cash provided by investing activities was $13.3 million for the nine months ended June 30, 2025, primarily from asset sales and cash acquired in the merger.
• The company secured debtor-in-possession (DIP) financing of up to $1.75 million for SRx Canada, expected to finance working capital needs during CCAA proceedings.
• The ELOC agreement with Keystone Capital Partners, LLC was increased to $1.0 billion, providing significant potential future capital access, subject to conditions.

Negatives

• There is substantial doubt about the company's ability to continue as a going concern due to recurring operating losses, negative operating cash flows, and a significant accumulated deficit.
• Net loss increased by 169% to $29.7 million for the nine months ended June 30, 2025, compared to $11.1 million in the prior year.
• Net sales decreased by 65% to $41.1 million for the nine months ended June 30, 2025, primarily due to liquidity constraints and operational disruptions.
• SRx Canada, the core specialty pharmacy business, has commenced CCAA proceedings (creditor protection), indicating severe financial distress.
• The company was not in compliance with financial covenants for its CWB term loans as of June 30, 2025, and September 30, 2024, making the entire $23.1 million debt callable.
• Goodwill impairment of $19.7 million was recognized for the Pharmacy and Prescription Drug Sales reporting unit in fiscal 2024 due to loss of a key contract and market pressures.
• The company received a notice from NYSE American regarding non-compliance with continued listing standards, risking delisting.
• The resale of up to 101,865,909 shares by selling stockholders represents approximately 51% of fully diluted outstanding common stock, indicating significant potential dilution and downward pressure on share price.
• Cash used in operating activities was $15.7 million for the nine months ended June 30, 2025, reflecting continued cash burn.
• The company's accumulated deficit grew to $98.4 million as of June 30, 2025, from $70.0 million at September 30, 2024.
• The U.S. pet food business (Halo) continues to experience significant liquidity constraints and operating losses, remaining reliant on external financing.

Risks

• Substantial doubt about the company's ability to continue as a going concern.
• Inability to successfully implement growth strategy or manage anticipated growth effectively.
• Loss of key members of senior management team.
• Inability to generate sufficient cash flow or raise capital on acceptable terms to run operations, service debt, and make necessary capital expenditures.
• Dependence on subsidiaries for payments, advances, and transfers of funds due to holding company status.
• Inability to successfully develop additional products and services or successfully market and commercialize them.
• Intense competition in the market.
• Inability to attract new and retain existing customers, suppliers, distributors, or retail partners.
• Allegations that products cause injury or illness or fail to comply with government regulations.
• Inability to manage supply chain effectively.
• Inability of the company or co-manufacturers and suppliers to comply with legal and regulatory requirements.
• Effect of potential price increases and shortages on inputs, commodities, and ingredients.
• Inability to develop and maintain brand and brand reputation.
• Non-compliance with data privacy rules.
• Non-compliance with applicable regulations issued by the U.S. Food and Drug Administration (FDA), the U.S. Federal Trade Commission (FTC), the U.S. Department of Agriculture (USDA), and other federal, state, and local regulatory authorities.
• Risk of products being recalled for various reasons, including product defects, packaging safety, and inadequate or inaccurate labeling disclosure.
• Risk of shifting customer demand in relation to raw pet foods, premium kibble, and canned pet food products, and failure to respond to such changes quickly and effectively.
• Impact of damage to or interruption of information technology systems due to cyber-attacks or other circumstances beyond control.
• Business interruptions resulting from geopolitical actions, including war and terrorism.
• The company's business and operations could be negatively affected by securities litigation or shareholder activism.
• SRx Health conducts its business in a highly regulated industry and environment, with varying provincial regulations in Canada.
• Changes in reimbursement programs, prescription drug pricing, and commercial terms could adversely affect SRx Health's operations and financial performance.
• Inflationary pressures may affect drug costs and other operating costs.
• SRx Health's business is highly competitive, with competitors having longer operating histories, larger customer bases, and greater resources.
• Profitability of pharmacy businesses depends on the interplay between brand name and generic drugs.
• Changes in drug development and prescription mix may impact SRx Health's results of operation.
• Product liability, product recall, or personal injury issues could damage SRx Health's reputation.
• The set shelf life of drug products may lead to inventory write-downs.
• Continued operation of SRx Health's distribution facilities is critical, and disruptions could negatively affect business.
• Conducting clinical trials involves a high degree of risk, including delays or stoppages beyond SRx Health's control.
• Negative results from clinical trials or adverse safety events involving product targets may impact future commercialization.
• SRx Health's insurance policies may not be sufficient to cover all claims.
• SRx Health is subject to a variety of business continuity hazards and risks, including natural disasters and utility failures.
• SRx Health's risk management policies and procedures may not be fully effective.
• Consumer opinion of SRx Health may be impacted by reputational damages to its suppliers.
• Healthcare professional errors may harm SRx Health's business and reputation.
• Consolidation in the supply chain may negatively impact drug prices and SRx Health's ability to compete.
• Reliance on third-party suppliers for a significant portion of product supply.
• Quarterly results of operations may fluctuate, potentially failing to meet investor expectations.
• Changes in tax and trade policies, tariffs, and other government regulations affecting trade between Canada and other countries could adversely affect SRx Health.
• Disruption of the global supply chain and ineffective service providers could adversely impact SRx Health's business.
• Failure to meet customer expectations may harm SRx Health's brand and reputation.
• Inability to keep pace with rapid developments in healthcare technology and changes in the industry.
• Use and disclosure of personally identifiable information, including personal health information, is subject to privacy and security regulations.
• Reliance on relationships with major drug manufacturers and specialty practitioners.
• Information technology systems impairment and cyber-attacks.
• Services must integrate and interoperate with a variety of operating systems, software, hardware, web browsers, and networks.
• Failure to properly manage inventories and anticipate demand.
• Reliance on data obtained from third-party sources, which may be inaccurate or unreliable.
• Change in population demographics could have an adverse effect on SRx Health's business.
• Inability to hire, retain, and motivate qualified personnel.
• Involvement in regulatory or agency proceedings, investigations, and audits.
• Labor-related matters, including labor disputes.
• Goodwill and other intangible assets could become impaired.
• Conflicts of interest may arise between SRx Health and its directors and officers.
• Risks associated with leasing space and equipment, including long-term non-cancelable leases.
• Inability to adequately protect proprietary and intellectual property rights.
• Being accused of infringing intellectual property rights of others.
• Impact of economic conditions, including the resulting effect on spending by consumers.
• Halo's ability to meet increases in demand may be impacted by reliance on suppliers and risk of shortages and long lead times.
• If Halo fails to maintain and expand its brand, or the quality of its products, its business could suffer.
• Halo may not be able to successfully implement and/or manage its growth strategy on a timely basis or grow at all.
• Halo's recurring losses and significant accumulated deficit have raised substantial doubt regarding its ability to continue as a going concern.
• If Halo does not successfully develop additional products and services, or if such products are not successfully commercialized, its business will be adversely affected.
• Halo is engaged in a highly competitive business, and inability to compete effectively could adversely affect results.
• If Halo fails to attract new customers, or retain existing customers, or fail to do either in a cost-effective manner, sales may not increase.
• Food safety and food-borne illness incidents may materially adversely affect Halo's business.
• Halo may not be able to manage its manufacturing and supply chain effectively.
• If any of Halo's independent shipping providers experience delays or disruptions, its business could be adversely affected.
• Halo's intellectual property rights may be inadequate to protect its business.
• Halo depends on the knowledge and skills of its senior management and other key employees, and if unable to retain and motivate them or recruit additional qualified personnel, its business may suffer.
• A failure of one or more key information technology systems, networks, or processes may materially adversely affect Halo's ability to conduct business.
• Halo relies heavily on third-party commerce platforms, and if one is compromised, its business could be harmed.
• Halo may face difficulties as it expands business and operations into jurisdictions with no prior operating experience.
• Decreased spending on pets in a challenging economic climate.
• Significant merchandise returns or refunds could harm Halo's business.
• Halo may seek to grow through acquisitions, investments, or strategic alliances, and failure to integrate and manage these could have an adverse effect.
• Premiums for Halo's insurance coverage may not continue to be commercially justifiable, and coverage may have limitations.
• Adverse litigation judgments or settlements relating to Halo's business operations.
• Failure to comply with the U.S. Foreign Corrupt Practices Act, other anti-corruption and anti-bribery laws, and applicable trade control laws.
• Halo's ability to utilize its net operating loss carryforwards may be limited.
• Halo and its co-manufacturers and suppliers are subject to extensive governmental regulation and may be subject to enforcement if not in compliance.
• International expansion of Halo's business could expose it to substantial business, regulatory, political, financial, and economic risks.
• Changes in government regulations and trade policies may materially and adversely affect Halo's sales and results of operations.
• Halo's products may be subject to recalls for various reasons.
• The company's holding company structure makes it dependent on subsidiaries for cash flow and could subordinate shareholder rights.
• Delaware law and the Certificate of Incorporation and Bylaws contain anti-takeover provisions.
• The Certificate of Incorporation designates a state or federal court within Delaware as the exclusive forum for substantially all disputes.
• The level of indebtedness and related covenants could limit operational and financial flexibility and adversely affect business if covenants are breached.
• Common stock may be deemed a penny stock, adversely affecting market price.
• Failure to meet NYSE American continued listing requirements could result in delisting.
• Common stock prices may be volatile.
• No expectation to pay cash dividends in the foreseeable future.
• Future sales of common stock, or the perception of such sales, may depress share price and dilute ownership.
• Market price of common stock may not attract new investors, and trading liquidity may not improve.
• Issuance of preferred stock whose terms could adversely affect voting power or value of common stock.
• Administrative and regulatory costs of public company compliance could consume significant resources.
• Being a smaller reporting company could make securities less attractive to investors and comparison difficult.
• The shares of Common Stock being offered in this prospectus represent a substantial percentage of outstanding shares, and sales could cause market price to decline significantly.
• Certain existing securityholders purchased securities at a price below current trading price and may experience a positive rate of return, while future investors may not.

Future Outlook

The company expects to require substantial additional capital to support operations and execute its business plan, primarily through equity or equity-based securities issuance. It does not expect to have positive cash flow until the end of 2025 or longer. Management believes increasing demand for specialty medications and health system capacity challenges will drive strong tailwinds for its Canadian Health Solutions model. The company intends to amend its registration statement to register an additional $972.45 million of common stock if authorized capital increases. Management is actively evaluating strategic alternatives for the U.S. pet food business, including potential restructuring, divestiture, or wind-down.

Management Comments

• Management believes that it is in the Company's best interests to have the flexibility to sell Common Shares pursuant to the ELOC Purchase Agreement, subject to market conditions.
• We expect to require substantial additional capital to support our operations and execute our business plan.
• We will be required to raise capital in part through the issuance of our equity or equity-based securities, the issuance of which may have an adverse effect on the price of our Common Stock.
• We expect that any net proceeds received by the Company from such sales to the Selling Stockholder will be used for working capital and general corporate purposes.
• At SRx, we make specialty healthcare simple for Canadians. We are a fully integrated Canadian healthcare services provider operating at the intersection of pharmacy, clinical services, and pharmaceutical distribution.
• Our mission is to simplify access to complex therapies and improve health outcomes for patients with chronic, rare, or specialty conditions.
• Looking ahead, we believe that increasing demand for specialty medications, alongside health system capacity challenges, will continue to drive strong tailwinds for our model.
• With an established footprint, a growing pipeline of partnerships, and a demonstrated ability to scale efficiently, SRx is well-positioned to expand our leadership role in Canada's specialty healthcare landscape.
• Management of the Company believes its overall relationships with its employees are positive and the strength of its team is a critical success factor in becoming the most innovative premium pet food company in the world.

Industry Context

The Canadian specialty pharmacy sector is characterized by growth and stability, driven by an aging population, increasing prevalence of chronic illnesses, and an expanding role for pharmacists. Specialty drug spending is outpacing traditional drugs, projected to account for over 50% of eligible insurance plan submissions by 2026. SRx Health's integrated network and storefront presence are positioned to capitalize on these trends, offering a differentiated scope of care compared to traditional pharmacies. However, the industry is highly competitive, with consolidation and pricing pressures. The pet health and wellness industry is also highly competitive, with growing pet humanization and consumer focus on health, but also subject to economic downturns affecting discretionary spending.

Comparison to Industry Standards

• SRx Health's network of 20 specialty pharmacies, 34 infusion clinics, and four clinical trials sites across all 10 Canadian provinces positions it as one of the most accessible providers of comprehensive specialty healthcare services in Canada, a fragmented market.
• The company's average reimbursement submission time of 1.3 business days from engagement is significantly faster than the estimated industry standard of three business days for patient support programs.
• SRx Health's brick-and-mortar retail presence for specialty pharmacies offers a key competitive advantage over competitors who often dispense from closed distribution facilities, allowing for face-to-face interaction.
• The Canadian pharmacy sector, in general, has historically been less susceptible to recessionary effects, with over 80% of operators achieving profitability, a benchmark SRx Health's current financial distress (net losses, CCAA) significantly underperforms.
• Halo's premium and super-premium pet products (retail price greater than $0.20 per ounce) compete in a market with established players like Mars, Nestlé, and General Mills, many of whom have greater financial resources and brand recognition.

Management Changes

Corporate Governance

Legal Proceedings

• SRx Canada obtained an Initial Order under the federal Companies Creditors Arrangement Act (CCAA) on August 12, 2025, initiating formal creditor protection proceedings.
• On December 6, 2024, Canadian Western Bank (CWB) provided the company a demand and notice of intention to enforce security relating to the credit agreement, for $43,276,671 plus accrued interest and costs, which was not paid by the December 16, 2024 deadline and remains outstanding.
• On December 17, 2022, SRx Health was subject to discipline from the Saskatchewan College of Pharmacy Professionals due to improper billing practices, resulting in a CAD$30,000 fine, repayment of CAD$73,795.40 overbilled, and reimbursement of CAD$25,875.00 investigation costs. This matter has been resolved and was deemed immaterial.
• The company is subject to tax examinations primarily for the years 2020 through 2024 in Canada.

Related Party Transactions

• During the fiscal year ended September 30, 2024, and the nine-month period ended June 30, 2025, prior to the Merger, SRx Canada engaged in non-interest-bearing working capital advances with its largest shareholder and entities under common control. These balances were subsequently forgiven and reclassified as capital contributions.
• During the pre-merger period in the three months ended June 30, 2025, net related party balances transitioned into a payable position, including a $1.4 million balance due to Adesh Vora, the company's former Chief Executive Officer. This was recorded as an increase to beginning accumulated deficit and a non-cash capital distribution.
• On August 14, 2025, the company entered into a Settlement, Share Forfeiture and Mutual Release Agreement with certain founders and officers of SRx Canada (Forfeiting Stockholders), including Adesh Vora, resulting in the forfeiture of approximately 18,839,332 Exchangeable Shares in consideration for release from certain claims.
• On April 25, 2025, the company entered into a consulting agreement with Terra Nova Business Holdings Inc., an arms-length party, for international logistics and business development services, with monthly consulting fees of $0.2 million and $8.6 million in prepaid expenses recorded as of June 30, 2025. The full prepaid amount was written off subsequent to June 30, 2025, following the CCAA filing.
• On August 25, 2025, the company issued 2,396,697 shares of restricted common stock as performance bonus compensation to certain directors, officers, and employees.
• On September 16, 2025, the company issued 196,000 shares of restricted common stock to certain current and former directors.
• Between July and September 2025, the company issued 394,780 shares of common stock to former employees and shareholders of SRx Canada who retracted their exchangeable shares.
• The company's revolving credit facility with Better Choice Company Inc. (BTTR) was personally guaranteed by Adesh Vora, former CEO of the Company, and the outstanding balance was converted into common shares upon the reverse merger closing.

Stakeholder Impact

• Shareholders face significant dilution from the resale of over 101 million shares by selling stockholders, representing 51% of fully diluted shares, and potential further dilution from future capital raises.
• Shareholders are exposed to substantial risk due to the 'going concern' warning, increased net losses, and the CCAA proceedings of SRx Canada, which could lead to a significant decline in share price or loss of investment.
• Creditors of SRx Canada are directly impacted by the CCAA proceedings, which provide protection from claims and involve a court-supervised restructuring or sale process.
• Employees of SRx Canada may face uncertainty and potential job reductions as part of the CCAA restructuring and efforts to streamline the cost structure.
• Customers of SRx Canada's specialty pharmacy business may experience service disruptions due to operational downsizing and liquidity constraints that limited access to high-cost medications.
• Suppliers to SRx Canada may face payment delays or renegotiated terms due to the CCAA proceedings and liquidity issues.
• Investors in the July and October PIPE Financings and the ELOC agreement are providing critical capital but are subject to the risks associated with the company's financial distress and the potential for further dilution.

Next Steps

• SRx Canada will continue CCAA proceedings to complete a Sale Process and identify transactions for the sale of all or substantially all of its business or assets.
• The company intends to carry on the critical business of SRx Canada throughout the pendency of the CCAA Proceedings.
• Management is actively evaluating strategic alternatives for the U.S. pet food business (Halo), including potential restructuring, divestiture, or wind-down.
• The company must submit a plan to regain compliance with NYSE American continued listing standards by November 13, 2025, with a deadline to cure the deficiency by July 14, 2026.
• The company intends to amend its Registration Statement to register an additional $972.45 million of Common Stock under the ELOC Purchase Agreement if its authorized capital increases.
• The company will seek stockholder approval at a special meeting to increase its authorized shares of Common Stock from 200,000,000 to 5,000,000,000.
• The company will be required to file a registration statement with the SEC to register for resale the Common Stock issuable upon conversion of Series A Preferred Stock and exercise of October Warrants.

Key Dates

Recommendation

The filing reveals a company in severe financial distress, with a 'substantial doubt about its ability to continue as a going concern' explicitly stated by management and auditors. Key negatives include a 169% increase in net loss, a 65% decline in net sales, negative operating cash flow, and the primary Canadian subsidiary (SRx Canada) entering creditor protection (CCAA proceedings). The company is in breach of debt covenants, making significant loans callable, and faces potential delisting from the NYSE American. While capital raises are ongoing, they come with massive dilution (51% of fully diluted shares offered for resale) and are reactive to a critical liquidity crisis. The U.S. pet health business (Halo) also suffers from liquidity constraints and operating losses. Given the profound financial instability, operational challenges, regulatory non-compliance, and significant dilution, the risk of substantial capital loss for investors is extremely high. A seasoned investor would likely view this as an unsustainable situation requiring immediate exit.

Keywords

Specialty Pharmacy, Pet Health, SEC Filing, Going Concern, CCAA Proceedings, Liquidity Crisis, Net Loss, Dilution, NYSE American Delisting Risk, Convertible Notes, Warrants, Asset Sales, Goodwill Impairment, Canada, United States, Pharmaceutical Distribution, Clinical Trials, Pet Food, Corporate Restructuring, Private Placement, Equity Line of Credit